Blockade of nociceptin/orphanin FQ receptor signaling reverses LPS-induced depressive-like behavior in mice  by Medeiros, Iris U. et al.
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a  b  s  t  r  a  c  t
Nociceptin/orphanin  FQ  is  the natural  ligand  of  a Gi-protein  coupled  receptor  named  NOP.  This  peptider-
gic  system  is involved  in the  regulation  of mood  states  and  inﬂammatory  responses.  The  present  study
aimed  to investigate  the  consequences  of blocking  NOP  signaling  in  lipopolysaccharide  (LPS)-induced
sickness  and depressive-like  behaviors  in  mice.  LPS  0.8 mg/kg,  ip, signiﬁcantly  induced  sickness  signs
such  as weight  loss,  decrease  of  water  and  food  intake  and  depressive-like  behavior  in  the tail  suspension
test.  Nortriptyline  (ip, 60 min  prior  the test)  reversed  the  LPS-induced  depressive  states.  The  NOP  receptor
antagonist  SB-612111,  30 min  prior  LPS, did not  modify  LPS-induced  sickness  signs  and  depressive-like
behavior.  However,  when  injected  24 h after  LPS,  NOP antagonists  (UFP-101,  icv, and  SB-612111,  ip)  sig-ipopolysaccharide-induced depressive
nﬂammation
epression
ail suspension test
niﬁcantly  reversed  the  mood  effects  of  LPS.  LPS  evoked  similar  sickness  signs  and  signiﬁcantly  increased
tumor  necrosis  factor-  (TNF-)  and interleukin-6  (IL-6)  plasma  levels  6 h post-injection  in wild-type
((NOP(+/+))  and NOP  knockout  ((NOP(−/−))  mice.  However,  LPS  treatment  elicited  depressive-like  effects
in NOP(+/+)  but not  in  NOP(−/−)  mice.  In conclusion,  the  pharmacological  and  genetic  blockade  of  NOP
signaling  does  not  affect  LPS  evoked  sickness  signs  while  reversing  depressive-like  behavior.
©  2015 Elsevier  Inc.  All  rights  reserved.ntroduction
Current preclinical and clinical depression studies have shown
hat activation of the immune system may  be involved in major
epression. This hypothesis was ﬁrst proposed based on the high
ncidence of immunological abnormalities in patients diagnosed
ith major depression compared to the general population [1] and
he development of depression in patients with no prior history
f affective disorders undergoing immunotherapy [2]. Subsequent
tudies have begun to establish a link between depression and
nﬂammatory conditions such as auto-immune diseases, multiple
clerosis, cardiovascular diseases, diabetes, obesity, as well as with
thers clinical conditions linked with inﬂammation such as asthma
nd allergies [3–6].
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196-9781/© 2015 Elsevier Inc. All rights reserved.Another interesting fact about the association between
depression and inﬂammation is the similarity of major depres-
sion symptomatology with sickness behavior. Proinﬂammatory
cytokines such as tumor necrosis factor- (TNF-) and interleukin-
1 (IL-1) and 6 (IL-6) induce behavioral changes such as sleep
alterations, cognitive dysfunctions, fatigue and anhedonia that are
related to alterations in the monoamine systems in brain regions
important to mood regulation (for a review see refs. [7,8]).
Considering the role of proinﬂammatory cytokines on depres-
sion, the systemic administration of lipopolysaccharide (LPS), an
activator of innate immune system, has been used to trigger
depressive-like behavior in rodents. LPS injections in rats and mice
induce both peripheral and central inﬂammation that may  result in
time related behavioral alterations such increased immobility time
in the forced swimming and tail suspension tests [9]. Treatment
with several classes of antidepressants can revert or prevent this
depressive-like behavior [10,11].Nociceptin/orphanin FQ (N/OFQ) is a seventeen-amino acid
peptide acting as the endogenous ligand of a G-protein coupled
receptor named N/OFQ peptide receptor (NOP) [12,13]. The pep-
tide precursor of N/OFQ (ppN/OFQ) and NOP receptor are broadly
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xpressed in the central nervous systems as well as in peripheral
rgans and in the immune system, and the binding of N/OFQ to the
OP receptor modulates a variety of physiological processes (for a
eview see ref. [14]).
A growing body of evidence is available in the literature about
he role played by N/OFQ-NOP receptor system in inﬂammation
nd depression (for a review see refs. [15,16]). NOP receptor antag-
nists evoke antidepressant-like effects in different animal models
f depression in rats and mice [17–22]. The same molecules when
dministrated to rodents produce beneﬁcial actions in inﬂam-
ation and sepsis, reducing the mortality in caecal ligation and
uncture model of sepsis in rats [23] and decreasing fecal bleed-
ng in mice dextran sodium sulfate-induced colitis [24]. In line
ith pharmacological ﬁndings, NOP receptor knockout studies cor-
oborated the hypothesis that the N/OFQ-NOP receptor plays an
mportant role in controlling inﬂammatory processes and depres-
ion. In fact, the lack of N/OFQ receptor is reported to attenuate
he development of colitis in a dextran sodium sulfate murine
odel [25]. On the other hand, knocking out the NOP receptor gene
nduces an antidepressant-like phenotype in behavioral despair
ssays both in mice [18,19] and rats [26]. Considering this back-
round, the present study aimed to investigate the participation of
/OFQ-NOP receptor in LPS induced sickness signs and depressive-
ike behavior in mice.
aterial and methods
nimals
Experiments were conducted using male Swiss mice breaded at
he Federal University of Rio Grande do Norte (Natal, Brazil), CD-1
ice from Harlan (Udine, Italy) and wild type (NOP(+/+)) and NOP
nockout (NOP(−/−)) mice, backcrossed on CD-1 strain, breaded at
he University of Ferrara (Ferrara, Italy). Mice were 12–16 weeks
ld (28–35 g) and were housed under standard conditions (22 ◦C,
2-h light:12-h dark cycle) with food and water ad libitum in plas-
ic cages. Swiss and CD-1 mice were housed in groups of 10–16
er cage (41 cm × 34 cm × 16 cm)  and NOP(+/+) and NOP(−/−) mice
ere housed in groups of 4 per cage (30 cm × 21 cm × 14 cm). Mice
rom Harlan were allowed to acclimatize for at least 7 days before
esting. A total number of 129 CD-1 mice, 153 Swiss mice, and
9 and 43 NOP(+/+) and NOP(−/−) mice, respectively, were used
o develop this study. Experiments performed in Brazil were con-
ucted in accordance with Brazilian law no. 11.794/2008 for care
nd use of experimental animals. Experiments performed in Italy
ere performed according to the European (2010/63/EU) and Ital-
an legislation (D. Lgs 26/2014). These protocols were approved by
oth the Ethic Committee for Animal Use of Federal University of
io Grande do Norte (License No. 042/2012), and the University of
errara and Italian Ministry of Health (Protocol No. 316/2013-B).
his study is reported following the ARRIVE guidelines [27].
rugs and treatments
LPS (serotype 0111:B4, Sigma, St. Louis, MO,  USA), nortriptyline
Medley Pharmaceutical Industry, Campinas, SP, Brazil), UFP-101
[Nphe1,Arg14,Lys15]N/OFQ-NH2, synthesized by Prof. Guerrini,
epartment of Pharmaceutical Sciences, University of Ferrara,
taly), and SB-612111 (Tocris Bioscience, Bristol, UK) were used.
PS and nortriptyline were both dissolved in saline solution, while
B-612111 was solubilized in dimethylsulphoxide (DMSO) in a
nal concentration not exceeding 0.8%. Stock solutions of UFP-101
50 mM)  were stored at −20 ◦C and were diluted to the desired
oncentration in saline before experiments.
LPS (0.8 mg/kg) was intraperitoneally (ip) administrated and
ehavioral and biochemical assays were performed at 6 or 24 h afteres 72 (2015) 95–103
injection. Nortriptyline (30 mg/kg, ip) was injected 60 min  before
the behavioral assays. The non-peptide NOP antagonist SB-612111
(10 mg/kg, ip) was administered following two  distinct protocols in
separate experimental groups: (1) 30 min  before LPS injection, and
(2) 30 min  before the tail suspension test. The peptide NOP antago-
nist UFP-101 (10 nmol/2 L) was injected intracerebroventricularly
(icv) 5 min  before the tail suspension test. Central injections were
made at the rate of 1 l/min through a needle (27 G) protruding
1 mm from the cannula tip. Control groups were treated with their
respective vehicles (saline or DMSO 0.8% solutions) following the
same schedule described to treatment groups. All drugs injected
ip were given in a volume of 10 ml/kg. All drugs were freshly pre-
pared before experiments. The doses of UFP-101 and SB-612111
employed in this study have been previously reported to induce
antidepressant-like actions in mice assessed in behavioral despair
tests [18–20,22].
Cannula implantation
Surgical implantation of cannula in lateral ventricle was  con-
ducted in mice anesthetized intraperitoneally with ketamine and
xylazine (100 and 10 mg/kg, respectively) and placed in a stereo-
taxic apparatus. An incision was  made in the skin to expose the
skull. A stainless-steel 8 mm guide cannula (25 mm × 0.7 mm)  was
implanted in lateral ventricle and was ﬁxed with dental cement.
Coordinates toward the bregma were lateral +1.1 mm,  posterior
−0.6 mm,  and ventral −1.0 mm [28]. To prevent occlusion, a dummy
cannula was inserted in the guide cannula. After surgery, pain
and inﬂammation were attenuated with subcutaneous diclofenac
sodium (10 mg/kg) administration and the animals were allowed to
recover for at least 4 days before tests. At the end of the experimen-
tal procedures, all animals were euthanized with an overdose of
sodium thiopental and perfused transcardially with saline solution.
The placement of the cannula was  veriﬁed under a light microscope.
Results of animals in which the cannula was not correctly placed
were excluded for further analysis (less than 10%).
LPS-induced sickness signs
Changes in rectal temperature, body weight, food and water
intake following LPS injection were used as parameters to evaluate
sickness. Rectal temperature was determined using a digital ther-
mometer (MicroTherma 2 T Hand Held Thermometer, 2Biological
Instruments, Besozzo, Italy) via a lubricated thermistor probe (2-
mm diameter) inserted 20 mm into the rectum. The probe was left
in place until steady readings were obtained (approximately 20 s).
The temperature was measured three times: before LPS injection,
and 6 and 24 h after. Body weight and food and water intake were
measured before and 24 h after LPS injection.
Tail suspension test
The test was  performed during the light cycle (between 09.00
and 13.00) as previously described by Steru et al. [29]. Mice were
isolated acoustically and visually and suspended, 50 cm above
the ﬂoor, by an adhesive tape placed 1 cm from the tip of the
tail. The total amount of time each animal remained immobile
(i.e. did not struggle) during the 6-min session was  recorded (in
seconds) as immobility time. The test was performed 24 h after LPS
injection.
Open ﬁeld testSpontaneous locomotor activity of mice was measured using
the open ﬁeld test. The apparatus, made of wood covered with
impermeable formica, had a black ﬂoor of 40 cm × 40 cm and black
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Table  1
Sickness signs assessed at 6 and 24 h after the LPS injection in Swiss and CD-1 mice.
Sickness signs Swiss mice CD-1 mice
Saline LPS Saline LPS
Rectal temperature 6 h (◦C) 36.95 ± 0.20 35.89 ± 0.26* 37.91 ± 0.23 37.17 ± 0.18*
Rectal temperature 24 h (◦C) 37.45 ± 0.14 37.54 ± 0.26 37.65 ± 0.51 37.97 ± 0.66
Loss  of body weight (g) 0.50 ± 0.53 −2.20 ± 0.46* −0.14 ± 0.14 −1.80 ± 0.44*
Food  intake (g) 6.25 ± 0.00 1.39 ± 0.00* 5.02 ± 0.20 2.81 ± 0.16*
0
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ata are the mean ± SEM of n = 8–10 Swiss mice/group; n = 14–15 CD-1 mice/group
alls of 40 cm high. The test room had a controlled illumination
dimly-light condition). Each mouse was placed in the center of
he open ﬁeld and the distance travelled (in meters) for 5 min  was
egistered, through automatic observation (Anymaze, Stoelting Co.,
ood Dale, IL, USA). After the behavioral evaluation of each mouse,
he arena was cleaned with 5% ethanol solution. This test was per-
ormed 30 min  after the tail suspension test.
erum levels of proinﬂammatory cytokines
At 6 h or 24 h after LPS injection, blood was collected by cardiac
uncture under isoﬂurane anesthesia and left 30 min  at room tem-
erature. Serum was obtained centrifuging the samples for 10 min
t 10,000 × g at 4 ◦C. Serum samples were stored frozen (−80◦) until
he analysis. TNF-, IL-1 and IL-6 in serum were measured using
 commercially available ELISA kits from Life Technologies Cor-
oration (Monza, Italy) and quantiﬁed using a microplate reader
450 nm)  (Sunrise microplate reader, Tecan Trading AG, Männedorf,
witzerland). The results were shown as picograms per milliliter
pg/ml). Assays were sensitive with lower limits of quantiﬁcation
t 3 pg/ml for IL-6 and TNF-, and 7 pg/ml for IL-1.
ata analysis
Data are expressed as mean ± SEM of n animals. Data were ana-
yzed using unpaired Student’s t-test or two-way ANOVA followed
y the LSD post-hoc test (independent factors: LPS injection and
OP antagonist or nortriptyline administration), as speciﬁed in ﬁg-
re legends. Differences were considered statistically signiﬁcant
hen p ≤ 0.05. For the statistical analysis Statistica software version
.0 (StatSoft Inc., Tulsa, USA) was used.
a
im
m
ob
ili
ty
t im
e
(s
)
Swiss 
0
50
100
150
.
im
m
ob
ili
ty
tim
e
(s
)
mice CD
*
-1 mice
*
b
di
st
an
ce
 tr
av
el
le
d 
(m
)
ig. 1. Effect of LPS (0.8 mg/kg, ip) or saline on immobility time (a) and distance travelled
ata  are the mean ± SEM of 11–12 Swiss mice/group and 14–16 CD-1 mice/group.*p < 0.0.77 ± 0.00* 6.22 ± 0.19 3.47 ± 0.26*
.05 vs. saline, according to unpaired Student’s t-test.
Results
LPS-induced sickness signs and depressive-like behavior in mice
The sickness response of mice challenged by LPS was  evalu-
ated at 6 and 24 h after injection. LPS injection in Swiss and CD-1
mice signiﬁcantly reduced rectal temperature at 6 h, but not at 24 h
post-injection (Table 1). Indeed, decrease of food and water intake
and loss of body weight was  observed at 24 h after LPS-challenge
(Table 1).
As shown in Fig. 1a, the administration of LPS signiﬁcantly
increased the immobility time of Swiss and CD-1 mice in the tail
suspension test (Swiss mice: t(21) = 3.20; CD-1 mice: t(27) = 2.36,
p < 0.05 for both strains). However, LPS treatment did not signiﬁ-
cantly affect mouse locomotion in the open ﬁeld (p > 0.05 for both
strains; Fig. 1b).
In a distinct experimental series performed in Swiss mice, the
effects of nortriptyline, a tricyclic antidepressant, were assessed
in LPS-treated mice in the tail suspension test. The administra-
tion of LPS signiﬁcantly increased the immobility time of mice,
which was reversed by nortriptyline (saline + saline: 75.2 ± 8.4;
saline + nortriptyline: 27.2 ± 6.2*; LPS + saline: 124.8 ± 8.1*;
LPS + nortriptyline: 22.1 + 6.3#; two-way ANOVA, LSD’s test,
*p < 0.05 vs. saline + saline, #p < 0.05 vs. LPS + saline, interaction
between factors: F(1,46) = 11.40).
Effects of NOP receptor antagonists on LPS-induced sickness and
depressive-like behavior in mice
The effects of SB-612111 pretreatment on the development of
LPS-induced sickness and depressive-like behavior in CD-1 mice are
0
5
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20
.
Swiss mice CD-1 mice
sa
LP
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S
 (b) in Swiss and CD-1 mice in the tail suspension and open-ﬁeld tests, respectively.
5 vs. saline, according to unpaired Student’s t-test.
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vig. 2. Effects of 30 min  pretreatment with SB-612111 (10 mg/kg, ip) or vehicle on r
B-612111 was  tested in CD-1 mice. Data are the mean ± SEM of 8–11 mice/group. 
llustrated in Figs. 2 and 3. As shown in Fig. 2, in this series of experi-
ents LPS injection did not signiﬁcantly reduce rectal temperature
Fig. 2a) but evoked body weight loss (p < 0.05, LPS injection factor:
(1,33) = 30.66; Fig. 2b) and decreased food (p < 0.05, LPS injec-
ion factor: F(1,33) = 161.72; Fig. 2c) and water intake (p < 0.05, LPS
njection factor: F(1,33) = 95.67; Fig. 2d) in a period of 24 h. The
dministration of SB-612111 (10 mg/kg, ip), 30 min  prior LPS, did
ot modify the sickness signs induced by the toxin.
As represented in Fig. 3, LPS increased the immobility time
f vehicle-treated mice in the tail suspension test (p < 0.05, LPS
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ig. 3. Effects of 30 min  pretreatment with SB-612111 (10 mg/kg ip) or vehicle on
he immobility time of control and LPS treated mice in the tail suspension test. SB-
12111 was tested in CD-1 mice. Data are the mean ± SEM of 8–11 animals. *p < 0.05
s.  control, two-way ANOVA followed by LSD post-hoc test.temperature (a), body weight (b), food (c) and water (d) intake in LPS treated mice.
05 vs. vehicle, two-way ANOVA followed by LSD post-hoc test.
injection factor: F(1,33) = 9.80; Fig. 3). This effect of LPS was  slightly
attenuated by the pretreatment with SB-612111; however, the NOP
antagonist did not signiﬁcantly counteract the effects of the toxin
in the tail suspension test.
The effects of NOP antagonists on the depressive-like behavior
induced by LPS are summarized in Fig. 4. Two  distinct NOP antag-
onists, UFP-101 (10 nmol, icv) (Fig. 4a) and SB-612111 (10 mg/kg,
ip) (Fig. 4b), injected 5 and 30 min  respectively before the tail sus-
pension test, signiﬁcantly reversed the increase of immobility time
induced by the toxin administered 24 h before the test. In this series
of experiments two-way ANOVA followed by the LSD’s post-hoc
test revealed an interaction between the independent factors (LPS
injection and NOP antagonists) for UFP-101 (p < 0.05, F(1,43) = 4.16;
Fig. 4a) and SB-612111 (p < 0.05, F(1,58) = 4.73; Fig. 4b) treatments.
Phenotype of NOP receptor knockout mice on LPS-induced
sickness signs and depressive-like behavior
NOP(+/+) and NOP(−/−) mice were injected with LPS (0.8 mg/kg)
and during a 24 h period sickness signs were registered. As shown
in Fig. 5a, no differences were detected in the basal body tem-
perature between NOP(+/+) and NOP(−/−) mice. However, ip LPS
signiﬁcantly decreased rectal temperature in both NOP(+/+) and
NOP(−/−) mice compared to saline (p < 0.05, Fig. 5a, LPS injec-
tion factor: F(1,36) = 7.40). No signiﬁcant differences were detected
in saline-treated NOP(+/+) and NOP(−/−) mice in terms of body
weight, water and food intake (Fig. 5b–d). Systemic LPS sig-
niﬁcantly decreased body weight (p < 0.05, LPS injection factor:
F(1,36) = 19.12; Fig. 5b) in NOP(+/+) and in NOP(−/−) mice com-
pared to saline. LPS also reduced food consumption and water
intake in both NOP(+/+) and NOP(−/−) mice but these effects were
less attenuated in NOP(−/−) animals (p < 0.05 for both parameters,
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erum proinﬂammatory cytokines levels in LPS-treated NOP
eceptor knockout mice
Serum levels of TNF-, IL-6 and IL-1 were evaluated in
OP(+/+) and NOP(−/−) mice collected at 6 and 24 h after LPS treat-
ent (Fig. 7). Only IL-6 levels were detectable in NOP(+/+) and
OP(−/−) mice injected with saline (Fig. 7e). Six hours after the
PS injection both NOP(+/+) and NOP(−/−) mice showed a signif-
cant increase in the serum levels of TNF- (p < 0.05, LPS injection
actor: F(1,37) = 22.88; Fig. 7a), and IL-6 (p < 0.05, LPS injection fac-
or: F(1,26) = 22.37; Fig. 7b). At this time the levels of TNF- induced
y LPS were similar between genotypes. Regarding the serum lev-
ls of IL-1, LPS injection did not signiﬁcantly affect this cytokine
evel in NOP(−/−) and NOP(+/+) (p > 0.05 for both factors; Fig. 7c).
wenty-four hours after LPS injection, no signiﬁcant differences
ere detected between control and LPS-treated mice and between
enotypes in the levels of TNF- (Fig. 7d), IL-6 (Fig. 7e) and IL-1
Fig. 7f).
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Discussion
In the present study we showed that systemic LPS evoked
sickness signs, such as decreased rectal temperature at 6 h, reduc-
tion of food and water intake besides weight loss registered in
a period of 24 h after administration. Additionally, a depressive-
like behavior assessed in the tail suspension test was observed
24 h post-LPS injection in Swiss, CD-1 and NOP(+/+) mice. In line
with the literature, low doses of LPS elicit in laboratory animals
a transitory but robust inﬂammatory process characterized by
sickness behavior, modulated by proinﬂammatory cytokines [30].
This behavior peaks after 2–6 h, and then gradually vanishes hours
after the exposure to the immune challenge. This is followed by the
appearance of a depressive-like behavior that peaks 24 h after LPS
injection and mimics some features of clinical depression, includ-
ing, among others, helplessness and anhedonia [7]. In this study, the
LPS-induced depressive-like behavior measured with the tail sus-
pension test was signiﬁcantly reversed by nortriptyline, a tricyclic
antidepressant drug. These observations support a robust and repli-
cable inﬂammation-induced depressive condition evoked by LPS in
distinct mice strains and, as previously reported in the literature,
standard antidepressants are able to reverse this depressive-like
state [10,11].
A growing body of preclinical evidence supports an
antidepressant-like effect due to the blockade of NOP recep-
tors. These ﬁndings have been obtained by using a range of
compounds (peptide and non-peptide antagonists), different
species (rat and mouse) and assays (behavioral despair and
chronic mild stress), and knockout studies demonstrating a highly
consistent antidepressant-like phenotype of NOP(−/−)  mice and
rats (for a review see ref. [16]). Herein, we have investigated
whether NOP receptors signaling might be implicated in the
LPS-induced depressive-like behavior in mice.
Aiming to further investigate the role of NOP receptor signaling
in depressive-like behavior of LPS-treated mice, NOP  knockout
mice were used. No major differences were detected between
NOP(+/+) and NOP(−/−) mice in terms of sickness behavior after
LPS administration. A slight but signiﬁcant difference was  reg-
istered only in the amount of water intake. Moreover no major
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ifferences were recorded between NOP(+/+) and NOP(−/−) mice
n terms of inﬂammatory response to LPS, measured as increas-
ng in serum levels of proinﬂammatory cytokines. These evidences
uggest that the endogenous N/OFQ-NOP signaling does not play
 major role in the modulation of the inﬂammatory response after
PS administration, at least for the parameters considered in this
tudy. On the contrary, signiﬁcant differences were displayed in the
ehavior of NOP(+/+) and NOP(−/−) mice subjected to the tail sus-
ension test 24 h after LPS administration. In fact, NOP(−/−) mice
isplayed signiﬁcantly lower immobility time in the tail suspen-
ion test compared to wild type animals. LPS signiﬁcantly increased
he immobility time of NOP(+/+) but it was completely inactive in
OP(−/−) mice. These observations support an antidepressant-like
henotype for LPS-challenged NOP(−/−) mice. The resistance of
ice lacking the NOP receptor to the behavioral effects of LPS can
e ascribed both to a different responsiveness to the neurobiologi-
al modiﬁcations induced by LPS soon after its administration that
ead to the development of depression, or to a different expression
f the despaired behaviors in the day of the tail suspension test.
Of note, using NOP(−/−) mice is not possible to discriminate
n which of these two processes the NOP receptor is important,
ince these mice lack the receptor in all the phases of the test.
o address this point antagonism studies have been performed
sing the selective NOP antagonist SB-612111 given before LPS
dministration and before the tail suspension test. Conﬁrming the
ata obtained with the genetic block of the receptor, SB-612111
id not change the sickness parameters of mice treated with LPS,
emonstrating that the N/OFQ-NOP signaling does not control the
ickness induced by LPS. Importantly, no signiﬁcant differences
ere recorded in the tail suspension test between mice treated
nd untreated with SB-612111 before LPS. These results suggest
hat the N/OFQergic signaling does not play a role in modulat-
ng the neural mechanisms that leads to a depressive-like state
fter LPS administration. On the contrary, when SB-612111 was
njected before the tail suspension test it was able to completely
lock the increase of immobility time induced by LPS, suppor-
ing a role of the NOP receptor in the expression of the despaired
ehavior induced by LPS. The results obtained with the non-peptide
ntagonist SB-612111 were conﬁrmed with the peptide NOP antag-
nist UFP-101, that given 5 min  before the tail suspension test,
ounteracts LPS-induced depressive-like behavior. Thus, knock-
ut studies, completed by antagonism studies, demonstrated the
nvolvement of the N/OFQ-NOP receptor system in the expression
ather than development of inﬂammation-induced depression. It
s worth noting that in this study the NOP antagonists SB-612111
nd UFP-101 given prior the tail suspension test did not signiﬁ-
antly changed per se immobility time of control mice. Previous
ata have shown the antidepressant-like effects of both antagonists
n the tail suspension test [19,20]. However, the different experi-
ental conditions may  explain these discrepant results. In previous
tudies, to improve response reliability, mice were submitted to
n initial 5-min training session of tail suspension 24 h before the
est. Due to these experimental differences, the immobility time
f control mice in the present study is signiﬁcantly lower (ran-
ing from 60 to 80 s) than in previous studies (ranging from 160
o 180 s). Therefore these large differences in baseline immobility
ime may  likely affect the sensitivity of the assay in detecting the
ntidepressant-like effects of NOP antagonists in control mice.
Considering that proinﬂammatory cytokines are deeply
nvolved in the pathogenesis of depression [31,32], in this study
he serum levels of TNF-, IL-6 and IL-1 were assessed at 6 and
4 h post-LPS injection in NOP(+/+) and NOP(−/− mice. Proinﬂam-
atory cytokines involved in the acute phase of inﬂammation are
eleased in a transient way after an immune challenge [33,34].
n agreement with the literature, the present study showed that
t 6 h post-LPS IL-6 and TNF- were signiﬁcantly increased ins 72 (2015) 95–103 101
NOP(+/+) mice. However, no signiﬁcant changes in IL-1 levels
were found, which is in agreement with published data that
showed the time point peak for this cytokine is at 2 h after LPS
challenge [35]. In line with the sickness signs, no signiﬁcant
differences were measured between NOP(+/+) and NOP(−/−)
mice on the levels of proinﬂammatory cytokines at 6 h after LPS
injection. These observations contribute to the view that the
blockade of NOP receptor signaling does not produce major effects
on the development of inﬂammation elicited by LPS. Indeed, 24 h
post-LPS injection proinﬂammatory cytokine levels returned to
basal values in NOP(+/+) and NOP(−/−) mice. This suggests that the
LPS-induced depressive-like phenotype in NOP(+/+) mice is not
due to an ongoing inﬂammatory process. Notably, no signiﬁcant
differences in the serum levels of proinﬂammatory cytokines
were observed between wild-type and NOP knockout mice at
24 h after LPS. Altogether, the antidepressant-like phenotype of
NOP(−/−) mice injected with LPS is not due to differences in
serum proinﬂammatory cytokine levels. Further experiments are
required to investigate if any difference in these or others proin-
ﬂammatory cytokines can be observed in brain tissue of NOP(+/+)
and NOP(−/−) mice. Moreover, the role of regulatory cytokines
such as IL-10 should be investigated in order to further understand
the participation of cytokines in the antidepressant-like phenotype
of NOP(−/−) mice.
As discussed above, present ﬁndings support the view that NOP
antagonists reverse, but not prevent, the LPS-induced depressive-
like states in mice. Little information is still available about the
mechanisms by which NOP antagonists could ameliorate this
depressive-like behavior. Actually, one important ﬁnding comes
from Buzas et al. [36] which reported that LPS, via proinﬂammatory
cytokines (IL-1 and TNF-), can act up-regulating ppN/OFQ mRNA
and immunoreactivity to N/OFQ in rat astrocyte cultures. Indeed,
the nuclear factor-B (NF-B) pathway seems to be involved in
LPS inducted N/OFQ biosynthesis, since NF-B inhibitors antago-
nized the effect of LPS on N/OFQ expression [36]. Another evidence
comes from mice challenged with the T-cell-activating bacterial
superantigen, Staphyloccocal enterotoxin A, that increased levels
of ppN/OFQ mRNA in the hypothalamus and amygdala [37]. Leggett
et al. [38] found that LPS signiﬁcantly increased ppN/OFQ tran-
script expression in the hypothalamus 4 h after injection compared
to saline. Therefore, it is possible that the increased production of
N/OFQ induced by immunological stimuli leads to an augmented
NOP receptor signaling, thus evoking an excessive inhibition on
monoaminergic neurotransmittion, with subsequent development
of the depressive-like states. A growing body of evidence supports
an inhibitory role played by NOP activation on monoaminergic neu-
rotransmittion. In fact, the activation of NOP receptors in the locus
ceruleus, dorsal raphe nucleus and ventral tegmental area directly
inhibits monoaminergic neurons. Additionally, the activation of
presynaptic NOP receptors inhibits monoamines release in the pre-
frontal cortex, amygdala, accumbens nucleus, and hippocampus,
which are involved in the control of mood-related behaviors (for a
review see ref. [16]). In this view, NOP antagonists could promote
the antidepressant-like effects in LPS-treated mice by counter-
acting the activation of NOP receptor signaling evoked by N/OFQ
derived from LPS stimulus (see Fig. 8).
An additional mechanism by which LPS may  promote
depressive-like effects involves the regulation of the expression of
the enzyme indoleamine 2,3 dioxygenase (IDO). Tryptophan is an
essential amino acid required for 5-HT synthesis, and metabolized
extrahepatically by IDO. This enzyme is highly inducible by proin-
ﬂammatory cytokines [39], thus reducing tryptophan availability
during inﬂammation which impairs serotonergic neurotransmis-
sion [40]. In this view, one study performed in T cells activated
with the superantigen SEB showed that N/OFQ strongly induces
IDO expression in these immune cells [41]. Therefore, N/OFQ during
102 I.U. Medeiros et al. / Peptides 72 (2015) 95–103
Fig. 8. Schematic representation of the mechanism by which N/OFQ-NOP receptor system modulates LPS-induced depressive states. The present ﬁgure summarizes the
effects of LPS in increasing proinﬂammatory cytokines expression. These cytokines stimulate ppN/OFQ expression in the brain, thus increasing NOP receptor signaling and
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nﬂammation could contribute to reduce tryptophan availability,
hus ultimately facilitating the depressive-like behavior observed
n mice 24 h after LPS. This mechanism cannot explain the acute
ntidepressant effects of NOP antagonists, but could give support
o the effects of N/OFQ-NOP receptor signaling in mediating the
epressive-like states of LPS (see Fig. 8).
onclusion
The present ﬁndings suggest that NOP antagonists are able
o counteract, but not prevent, the LPS-induced depressive-like
ehaviors. NOP(−/−) mice are insensitive to the depressive-like
ffects of LPS; however, no differences in the development of
ickness signs and proinﬂammatory cytokines levels have been
bserved between wild type and NOP knockout mice. Ulti-
ately, this study highlights the involvement of the N/OFQ-NOP
eceptor system in the expression rather than development of
nﬂammation-induced depression.
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